Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach.

[1]  Claire Williams,et al.  Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  K. Gohil.  Exciting Therapies Ahead in Prostate Cancer. , 2015, P & T : a peer-reviewed journal for formulary management.

[4]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[5]  M. Woodward,et al.  A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation , 2014, Heart.

[6]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[7]  Jeffrey D. Miller,et al.  Current challenges in health economic modeling of cancer therapies: a research inquiry. , 2014, American health & drug benefits.

[8]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[9]  R. R. Holman,et al.  UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.

[10]  Noemi Kreif,et al.  Overview of Parametric Survival Analysis for Health-Economic Applications , 2013, PharmacoEconomics.

[11]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[12]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[13]  A. Adler,et al.  NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. , 2012, The Lancet. Oncology.

[14]  A. Boonen,et al.  A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[15]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[16]  P Barton,et al.  Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. , 2011, Health technology assessment.

[17]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[18]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[19]  G. Livingston,et al.  Cost effectiveness of memantine in Alzheimer's disease in the UK , 2010, Journal of medical economics.

[20]  Peter Lindgren,et al.  Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden , 2009, International Journal of Technology Assessment in Health Care.

[21]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[22]  P. Geborek,et al.  Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data , 2009, Scandinavian journal of rheumatology.

[23]  G. Haas,et al.  The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. , 2008, The Canadian journal of urology.

[24]  P Barton,et al.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. , 2006, Health technology assessment.

[25]  R. Holman,et al.  A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) , 2004, Diabetologia.

[26]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[27]  J. Caro,et al.  Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. , 2003, Clinical therapeutics.

[28]  J. Caro,et al.  Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care , 2001, Neurology.

[29]  L. Leng,et al.  Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. , 2015, Clinical and experimental rheumatology.

[30]  P Barton,et al.  The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. , 2002, Health technology assessment.